Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Net Income (2016 - 2019)

Alterity Therapeutics has reported Net Income over the past 3 years, most recently at -$3.8 million for Q4 2018.

  • For Q4 2018, Net Income fell 37.71% year-over-year to -$3.8 million; the TTM value through Jun 2019 reached -$6.6 million, down 19.77%, while the annual FY2025 figure was -$7.9 million, 37.22% up from the prior year.
  • Net Income for Q4 2018 was -$3.8 million at Alterity Therapeutics, down from -$2.8 million in the prior quarter.
  • Over five years, Net Income peaked at -$2.7 million in Q4 2016 and troughed at -$3.8 million in Q4 2018.
  • A 3-year average of -$3.1 million and a median of -$2.8 million in 2017 define the central range for Net Income.
  • Biggest five-year swings in Net Income: dropped 1.55% in 2017 and later tumbled 37.71% in 2018.
  • Year by year, Net Income stood at -$2.7 million in 2016, then fell by 1.55% to -$2.8 million in 2017, then plummeted by 37.71% to -$3.8 million in 2018.
  • Business Quant data shows Net Income for ATHE at -$3.8 million in Q4 2018, -$2.8 million in Q4 2017, and -$2.7 million in Q4 2016.